Low‐and middle‐income countries (LMIC) face unique challenges with regard to the
establishment of robust pharmacovigilance systems capable of generating data to inform …

New diagnoses of HIV infection have decreased among women in the USA overall, but
marked racial and geographical disparities persist. The federal government has announced …

With more than 1· 2 million people living with HIV in the USA, a complex epidemic across the
large and diverse country, and a fragmented health-care system marked by widening health …

Pregnant or potentially pregnant women have historically been excluded from clinical trials
of new medications. However, it is increasingly recognised that it is imperative to generate …

Background Dolutegravir (DTG) is a preferred regimen for all people with HIV including
pregnant women, but its effects on the fetus are not fully understood. Periconceptional …

Background: The transition to dolutegravir-containing antiretroviral therapy (ART) in low-and
middle-income countries (LMICs) was complicated by an initial safety signal in May 2018 …

Abstract Introduction As new antiretrovirals (ARVs), including long‐acting ARVs for treatment
and prevention, are approved and introduced, surveillance during pregnancy must become …

Background: Without treatment, HIV infection in pregnant women is associated with adverse
pregnancy outcomes. We compared adverse pregnancy outcomes among HIV-positive …

Background: Concerns have been voiced that the exclusion of pregnant women from clinical
trials results in a lack of safety and pharmacokinetic data for antiretroviral drugs (ARVs) in …

Background: In this study, an investigation was conducted on clinical drug trials comprising
pregnant women in China that provided data on the quantity, properties, source of funding …